Sourianarayanane Achuthan, Talluri Jyothsna, Humar Abinav, McCullough Arthur J
aDivision of Gastroenterology, Hepatology and NutritionbDepartment of Transplant Surgery, University of Pittsburgh Medical Center, Pittsburgh, PennsylvaniacDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WisconsindDepartment of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic FoundationeCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Eur J Gastroenterol Hepatol. 2017 May;29(5):516-523. doi: 10.1097/MEG.0000000000000825.
Hepatic venous pressure gradient (HVPG) measurement correlates with staging of liver fibrosis. Patients with nonalcoholic steatohepatitis (NASH) have a different pattern of fibrosis compared with hepatitis C virus (HCV) with possible alterations in pressures.
The aim of this study was to compare portal pressures with the stage of fibrosis in NASH in comparison with other liver diseases.
Records of all patients who had undergone transjugular liver biopsy with pressure measurements between January 2001 and June 2013 were reviewed. Wedge hepatic venous pressure (WHVP) and HVPG were compared with stages of fibrosis in liver diseases of different etiologies.
Among 142 patients included in this study, the liver disease etiology was as follows: HCV (26.6%) and NASH (24.6%), with the remaining (38.7%) grouped under other categories. The mean age of the patients was 51.2±11.5 years, with more men with HCV (73.1%) compared with NASH (51.4%) in terms of etiology (P=0.046). There were strong correlations between the stage of fibrosis with both the HVPG (r=0.64; P<0.0001) and the WHVP (r=0.63; P<0.0001) in NASH patients. Compared with HCV patients, NASH patients had a lower HVPG (3.4±2.4 vs. 7.5±11 mmHg/stage; P=0.01) with a coefficient estimate of -0.24 (P=0.017) and WHVP (9.6±5.5 vs. 14.6±15.2 mmHg/stage; P=0.03) for the stage of fibrosis.
HVPG and WHVP measurements were strongly correlated with stages of fibrosis in NASH. Patients with NASH had lower HVPG and WHVP for each stage of fibrosis compared with HCV patients. This raises the concern of underestimation of pressures by HVPG in NASH etiology for the stage of disease or increased fibrosis despite lower pressures in them.
肝静脉压力梯度(HVPG)测量与肝纤维化分期相关。与丙型肝炎病毒(HCV)感染患者相比,非酒精性脂肪性肝炎(NASH)患者的纤维化模式不同,压力可能存在改变。
本研究旨在比较NASH患者与其他肝病患者的门静脉压力与纤维化分期情况。
回顾了2001年1月至2013年6月期间所有接受经颈静脉肝活检并测量压力的患者记录。将肝静脉楔压(WHVP)和HVPG与不同病因肝病的纤维化分期进行比较。
本研究纳入的142例患者中,肝病病因如下:HCV(26.6%)和NASH(24.6%),其余(38.7%)归为其他类别。患者的平均年龄为51.2±11.5岁,就病因而言,HCV患者中男性更多(73.1%),而NASH患者中男性占比为51.4%(P = 0.046)。NASH患者的纤维化分期与HVPG(r = 0.64;P < 0.0001)和WHVP(r = 0.63;P < 0.0001)均密切相关。与HCV患者相比,NASH患者的HVPG较低(3.4±2.4 vs. 7.5±11 mmHg/分期;P = 0.01),纤维化分期的系数估计值为 -0.24(P = 0.017),WHVP也较低(9.6±5.5 vs. 14.6±15.2 mmHg/分期;P = 0.03)。
HVPG和WHVP测量与NASH的纤维化分期密切相关。与HCV患者相比,NASH患者在每个纤维化分期的HVPG和WHVP都较低。这引发了人们对于在NASH病因中,HVPG可能低估疾病分期压力或尽管压力较低但纤维化仍增加的担忧。